Scynexis (SCYX) Consolidated Net Income (2013 - 2026)
Scynexis' (SCYX) quarterly Consolidated Net Income came in at -$16.4 million in Q1 2026, down 204.75% YoY from $15.7 million in Q1 2025, and down 234.03% on a QoQ basis from $12.3 million in Q4 2025.
Scynexis (SCYX) Consolidated Net Income (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 13 years of Consolidated Net Income data on file, last reported at -$16.4 million in Q1 2026.
- Quarterly Consolidated Net Income fell 204.75% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.6 million (up 27.61% YoY) and the FY2025 annual result came in at -$8.6 million, up 59.65% from the prior year.
- Consolidated Net Income retreated to -$16.4 million in Q1 2026, from $12.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $122.3 million in Q2 2023 to a low of -$33.9 million in Q1 2023.
- A 5-year average of -$2.9 million and a median of -$6.9 million in 2025 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income sank 4789.92% — and 2023, when it soared 1016.15%.
- Tracing SCYX's Consolidated Net Income over 5 years: stood at -$19.5 million in 2022, then decreased by 9.06% to -$21.3 million in 2023, then soared by 78.92% to -$4.5 million in 2024, then soared by 373.49% to $12.3 million in 2025, then slumped by 234.03% to -$16.4 million in 2026.
- The last three Consolidated Net Income figures came in at -$16.4 million (Q1 2026), $12.3 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Scynexis | 61.87 Mn | -52.82 Mn | - | -7.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.48 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -21.27 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -19.50 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -605,000.00 |